Pfizer’s $10.4B Cash Flow Covers 93.3% of $9.7B Dividends Despite Patent Cliff
Pfizer generated $10.4B free cash flow in the 12 months ending Sept.30, 2025, covering 93.3% of its $9.7B dividend despite a 99.4% earnings payout ratio and patent expiries for Eliquis and Xeljanz. It plans to offset patent losses by investing in oncology drug PF-08634404 through its $43B Seagen acquisition.
1. Dividend Safety and Cash Flow Health
Pfizer enters 2026 with a forward dividend yield near 6.9% and an earnings-based payout ratio of 99.4%, prompting questions about sustainability. However, the company generated $10.4 billion in free cash flow over the 12 months ending September 30, 2025, versus $9.7 billion paid in dividends, resulting in a free cash flow payout ratio of 93.3%. This indicates that despite non-cash charges inflating the earnings denominator, Pfizer’s operations are producing sufficient cash to cover its distribution. Investors should note the firm’s 16-year streak of annual dividend increases and an unbroken record of 349 quarterly payouts dating back to 1937, which add both historical credibility and pressure on management to maintain the program.
2. Patent Cliff and Management’s Capital Allocation Strategy
Pfizer faces imminent loss of U.S. exclusivity for key franchises: blood thinner Eliquis and autoimmune therapy Xeljanz in 2026, followed by cancer drugs Ibrance and Xtandi in 2027. Combined, these four brands have generated annual sales exceeding $20 billion at their peaks. To counteract looming revenue declines, management has reiterated its commitment to sustaining and growing the dividend, while reallocating capital toward recently acquired and launched assets. CFO David Denton emphasized on the Q3 earnings call that reinvestment into products like the novel oncology candidate PF-08634404 and anti-obesity assets will offset losses of exclusivity over the next several years.
3. Pipeline Prospects and Long-Term Growth Drivers
Looking beyond near-term revenue headwinds, Pfizer is banking on its advanced pipeline to restore growth. The oncology portfolio was bolstered by the $43 billion acquisition of Seagen and the licensing of PF-08634404 from 3SBio; multiple late-stage trials are underway, with interim data expected in 2026. In weight management, phase 2 success of MET-097i has paved the way for phase 3 initiation in both obesity and type 2 diabetes, offering a differentiated once-monthly GLP-1 profile. Investors with a multi-year horizon should monitor these clinical readouts, as positive results could materially enhance Pfizer’s revenue base and further underpin dividend coverage post-2026.